Literature DB >> 15620351

Mannose 6-phosphate receptor dependence of varicella zoster virus infection in vitro and in the epidermis during varicella and zoster.

Jason J Chen1, Zhenglun Zhu, Anne A Gershon, Michael D Gershon.   

Abstract

Varicella zoster virus (VZV) is a highly infectious human pathogen; nevertheless, infectious virions are not released in vitro where infection is cell associated. Four VZV envelope glycoproteins contain mannose 6-phosphate (Man 6-P), and Man 6-P blocks infection of cells by cell-free VZV. Expression of antisense cDNA or siRNA-like transcripts were used to generate five stable human cell lines deficient in cation-independent mannose 6-phosphate receptors (MPRci). All 5 MPRci-deficient lines resisted infection by cell-free, but not cell-associated, VZV, secreted lysosomal enzymes, and released infectious virions when infected by cell-associated VZV. Intracellular MPRci thus appear to divert newly enveloped VZV to late endosomes, and plasmalemmal MPRci are necessary for entry by cell-free VZV. Biopsies from VZV-infected human skin supported the idea that because MPRci expression is naturally lost in maturing superficial epidermal cells, these cells do not divert VZV to endosomes and constitutively secrete infectious VZV.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15620351     DOI: 10.1016/j.cell.2004.11.007

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  70 in total

1.  Role for the αV Integrin Subunit in Varicella-Zoster Virus-Mediated Fusion and Infection.

Authors:  Edward Yang; Ann M Arvin; Stefan L Oliver
Journal:  J Virol       Date:  2016-07-27       Impact factor: 5.103

Review 2.  Pathogenesis and current approaches to control of varicella-zoster virus infections.

Authors:  Anne A Gershon; Michael D Gershon
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

3.  Varicella-zoster virus infection of human fibroblast cells activates the c-Jun N-terminal kinase pathway.

Authors:  Heidi J Zapata; Masako Nakatsugawa; Jennifer F Moffat
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

4.  Varicella-zoster virus infection induces autophagy in both cultured cells and human skin vesicles.

Authors:  Marie-Noëlle Takahashi; Wallen Jackson; Donna T Laird; Timothy D Culp; Charles Grose; John I Haynes; Luca Benetti
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

5.  Myelin-associated glycoprotein mediates membrane fusion and entry of neurotropic herpesviruses.

Authors:  Tadahiro Suenaga; Takeshi Satoh; Pranee Somboonthum; Yasushi Kawaguchi; Yasuko Mori; Hisashi Arase
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

6.  Functions of the unique N-terminal region of glycoprotein E in the pathogenesis of varicella-zoster virus infection.

Authors:  Barbara Berarducci; Jaya Rajamani; Leigh Zerboni; Xibing Che; Marvin Sommer; Ann M Arvin
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-04       Impact factor: 11.205

Review 7.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

8.  Retinoic acid prevents Chlamydia pneumoniae-induced foam cell development in a mouse model of atherosclerosis.

Authors:  Shinn-Jong Jiang; Lee Ann Campbell; Mark W Berry; Michael E Rosenfeld; Cho-Chou Kuo
Journal:  Microbes Infect       Date:  2008-07-17       Impact factor: 2.700

9.  Red-mediated transposition and final release of the mini-F vector of a cloned infectious herpesvirus genome.

Authors:  Felix Wussow; Helmut Fickenscher; B Karsten Tischer
Journal:  PLoS One       Date:  2009-12-04       Impact factor: 3.240

10.  Insulin degrading enzyme induces a conformational change in varicella-zoster virus gE, and enhances virus infectivity and stability.

Authors:  Qingxue Li; Mir A Ali; Kening Wang; Dean Sayre; Frederick G Hamel; Elizabeth R Fischer; Robert G Bennett; Jeffrey I Cohen
Journal:  PLoS One       Date:  2010-06-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.